

## Cancer Therapy - Impact

### Low Metabolism Rate

Impact on overall energy production Conversion

## Lower Body Immunity

Reduced tolerance to microbial load & prone to secondary infectioins

### • Fatigue & Anorexia

Loss of Appetite and reduced energy supply to the body

## Our Solution

• Increased Cellular Metabolism

High Performance Plant Extract with Highly Bioavaliability

• Stimulation Immune Pathways

Potentiate the pathway by Natural Compound Intervention

Aid in Translational Pathways

Low dose of Botanical Extract with high calorific value to promote transcriptional and translational pathways


## Our Technology

- GRAS Formulation Ingredeint
- PDT Potentiate activity by 10 -25x
- 95% Absorbed
- Traverse across the Body
- Safe on Gut, Liver & Kidney
- Technology Patent Filed


# Our Solution Impact

RELAPSE PREVENTI ON

20				
CRITERIA CONSIDERED	CANCER TREATMENT			POST CHEMOTHERAP Y CARE
	CHEMOTHERAPY	RADIATION	IMMUNOTHERAPY	ONCOWEL
TUMOR SIZE		Ţ	<b>↓</b>	NO EFFECT (POST CHEMOTHERAPY PATEINT CARE)
IMMUNE SYSTEM	Ţ			
METABOLISM	Ţ	<b>↓</b>	1	1
TOXICITY	1	1	DIFFERENT TOXICITIES THAT REQUIRE IMMUNOMODULATO RS AND STEROIDS	<b>↓</b>
CHRONIC PAIN AND SWELLING		RARE		
PRIMARY AND SECONDARY INFEACTION RISK				



# What we are solving



Challenge

❖Solubility & Delivery

Failing Efficacy


 Unique Technology Opportunity

Effective systemic absorption via oral route


Hybrid Action Therapy

Safety

Natural Based



# Technology - Delivery POC





### Non Technology Actives


☐Permeation by parallel artificial membrane permeation assay (PAMPA)

### **Oncowel Based Actives**

☐ Permeation by parallel artificial membrane permeation assay (PAMPA)








### **Market Size**

The global cancer therapy market was valued at approximately USD 158 billion in 2020, and it is expected to witness a revenue of USD 268 billion in 2026, with a CAGR of 9.15% over the forecast period.

**145.0 Billion** 

Total Available Market (TAM)

# Business Strategy



### Long term strategic partnerships

A double model, to generate growth:



#### 1. License agreements:

Lump sum payments: upfront, milestones

+ Royalties on sales



### 2. Supply agreements

### Commercialization model



#### Target population

Subjects at risk of developing metabolic diseases




#### Advisors

 $Health care \, professionals$ 




#### Retail

Pharmacies / drugstores
Network online + ad hoc omnichannel strategy by country



## Project Governance Team



Dr. Rajendra Bhandari Chairman - Focelite



Dr.RadheShyam Naik Oncology Expert



Vijay Kumar Ranka Managing Director



Dr. Praveen S Sancheti Clinical advisor



Manish S Shah Program partner



Dr.Jagdeep Kakadia Medical Advisor

